Cerca Magnetics, a pioneering spinout from the University of Nottingham, has successfully secured £3.8 million in a Series A funding round. The investment, led by Guinness Ventures, will accelerate the company's mission to revolutionize neurological diagnostics with its wearable brain scanner. This capital infusion marks a significant milestone, enabling the firm to advance its quantum-based technology into clinical applications.
Revolutionizing Brain Imaging Technology
The company has developed an innovative magnetoencephalography (MEG) system that utilizes quantum sensors to measure neural activity with exceptional precision. Unlike traditional fixed scanners, Cerca's technology employs lightweight, wearable sensors known as optically pumped magnetometers. This design allows patients, including infants for the first time, to move naturally during scans, overcoming major limitations.
This technological leap forward significantly enhances the accessibility of brain imaging, particularly for pediatric patients. The ability to conduct scans on mobile subjects opens new avenues for understanding conditions like epilepsy, multiple sclerosis, and dementia. Ultimately, the system promises to improve diagnostic accuracy and provide deeper insights into brain function.
Strategic Funding for Clinical Expansion
The £3.8 million ($4.75 million) investment round, spearheaded by Guinness Ventures, places Cerca Magnetics at a post-money valuation of £30 million. This financial backing reflects strong investor confidence in the company's technology and its potential to disrupt the neuroimaging market. The funding provides the necessary resources for the company to execute its ambitious growth plans.
Cerca Magnetics will allocate the new capital towards several key strategic objectives to facilitate its transition into clinical healthcare. A primary focus will be on obtaining clinical approval for its device in both the United Kingdom and the United States. The funds will also support the scaling of manufacturing operations and fuel a broader international expansion.
Proven Market Traction and Diverse Applications
The company has already demonstrated significant commercial success and market validation prior to this funding round. Cerca Magnetics has sold 19 of its advanced systems to leading neuroscience centers across 12 different countries. This global footprint is complemented by an annual sales growth rate exceeding 100 percent over the last three years.
The technology is currently being applied in high-impact research projects worldwide, showcasing its versatility. For instance, The Hospital for Sick Children in Toronto is using the system to study autism in children. A £2.8 million UK Ministry of Defence project is also leveraging the technology to assess blast exposure effects on military personnel.
Leadership Vision and Investor Confidence
David Woolger, CEO and co-founder of Cerca Magnetics, stated that the investment enables a decisive move into clinical applications. He emphasized the company's goal of making advanced brain imaging more accessible to support earlier diagnosis and better treatment. This funding is pivotal for scaling the technology for routine use in hospitals internationally.
Ashley Abrahams, Head of Origination at Guinness Ventures, expressed strong confidence in the company's trajectory. He noted that Cerca addresses a clear unmet need with a technology that is both scientifically advanced and practical for real-world use. Guinness Ventures believes the company is well-positioned to become a global leader in next-generation neuroimaging.
This Series A funding round represents a transformative moment for Cerca Magnetics, equipping it with resources to scale its groundbreaking technology. The investment validates the company's innovative approach to neuroimaging and accelerates its journey from research labs to clinical settings. With this support, Cerca is poised to make a lasting impact on the diagnosis of neurological conditions worldwide.